20
Zydus Lifesciences Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is RIVASTIGMINE USP, with a corresponding US DMF Number 27516.
Remarkably, this DMF maintains an Active status since its submission on September 30, 2013, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of February 06, 2014, and payment made on September 25, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II